Business Wire

AUTOFLEET/BLUEBIRD/ABEAM

22.4.2021 15:02:11 CEST | Business Wire | Press release

Share
Bluebird Partners With Autofleet and ABeam to Optimize and Scale One of Asia’s Largest Taxi Fleets

Bluebird Group (Bluebird), Indonesia’s leading taxi operator, has engaged with Autofleet and ABeam Consulting for a project to support its national fleet of over 23,000 vehicles with Autofleet’s Vehicle-as-a-Service platform. Bluebird and Autofleet have entered into a commercial agreement that is scheduled to roll out for vehicles operating in Jakarta and the surrounding area as soon as Q2 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210422005276/en/

By leveraging the Autofleet platform, Bluebird will be able to optimize its fleet’s vehicle placement, match and predict drivers based on demand forecasting to reduce empty rides, optimize allocation efficiency, allow for greater availability in traditionally under-served areas, reduce customer ETAs and improve overall customer experience. Autofleet is ingesting data from rides requested through the operator’s digital app and through traditional street hailing. These inputs are combined with real-time traffic data, weather forecasts, local events and other data points for increased demand prediction accuracy.

“The demand for mobility services has evolved, and it poses challenges that can only be solved by a combination of AI driven technology, and best in class operations. It is Bluebird’s value and commitment to deliver such customer-centric innovation through sustainable cooperation with our strategic partners, Autofleet and ABeam Consulting,” said Paul Soegianto, Chief Strategy Officer of PT Blue Bird Tbk.

In business for nearly 50 years, Bluebird serves millions of passengers every month. The fleet includes regular taxis (Bluebird & Pusaka), executive taxis (Silverbird), limousines and car rentals (Goldenbird), bus charters (Bigbird) and logistics (Birdkirim) among others. Autofleet’s platform will be integrated into the current dispatch infrastructure, supporting Bluebird, Silverbird and Birdkirim services in its first phase. In the longer term, the collaboration will inform Bluebird’s expanded activities in logistics and delivery services as well as exploration of new mobility infrastructure including electric vehicle (EV) charging.

“We are excited to partner with Bluebird, already a leader in mobility services in Southeast Asia, and apply the Autofleet platform to power current operations and prepare the business for future strategy and growth,” said Kobi Eisenberg, CEO at Autofleet. “Deploying Autofleet's platform will keep Bluebird at the cutting edge of the mobility industry, providing an outstanding customer experience, in a very competitive market.”

“ABeam Consulting is thrilled to support and expand Bluebird’s innovative services through AI and machine learning to increase operational efficiency,” said Tatsuya Kamoi, CEO at ABeam Consulting. “With our deep expertise in Mobility as a Service, we will support Bluebird’s operations and apply industry best practices to stay competitive with leading rideshare companies.”

In September 2020, Autofleet and ABeam Consulting entered a partnership to offer a comprehensive solution that supports Mobility as a Service (MaaS) projects end-to-end from the proposal stage to system implementation. Following projects in Japan and Cambodia, the engagement with Bluebird was secured through a year-long competitive proposal process and represents the largest commercial fleet management opportunity arising from the partnership to date.

About Autofleet
Autofleet provides the leading Vehicle-as-a-Service platform for fleets to optimize existing operations and to seamlessly launch new business models from existing assets. The platform leverages advanced machine-learning algorithms for demand prediction, optimized placement and matching, automated pit-stop management and in/de-fleeting, and more. For more information, please visit https://www.autofleet.io/ .

About ABeam Consulting
ABeam Consulting Ltd., headquartered in Tokyo having 6,600 people serve more than 1,100 clients throughout Asia, in the Americas and Europe with its 28 offices since 1981, providing consulting services across various industries and with an expertise in digital transformation services that create strategic advantage, improve business processes, leverage technology innovation and enhance organizational performance.

Please contact and visit us under https://www.abeam.com/jp/en for more details.

About Bluebird
Established in 2001, PT Blue Bird Tbk (BIRD), is a public transportation company catering to passengers and providing other land transportation services. PT Blue Bird Tbk's 15 subsidiaries are found in 18 major cities around the country, namely Jakarta, Depok, Tangerang, Bekasi, Cilegon, Medan, Manado, Bandung, Palembang, Balikpapan, Padang, Pangkalpinang, Batam, Bali, Lombok, Semarang, Surabaya, Pekanbaru, Makassar, Solo and Yogyakarta.

Bluebird is committed to always provide safe, reliable, and comfortable transportation with easy accessibility for its customers. Companies extensive network covers more than 600 exclusive taxi outlets placed in malls, shopping centers and other strategic places. Serving millions of passengers every month.

Since going public on the Indonesia Stock Exchange in 2014, PT Blue Bird Tbk has gained status as a reliable and trustworthy transportation partner.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye